99 related articles for article (PubMed ID: 22988059)
1. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
2. Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
Schonewolf CA; Patel B; Gensure RH; Narra V; Haffty BG; Nosher JL; Jabbour SK
Am J Clin Oncol; 2014 Jun; 37(3):234-40. PubMed ID: 23275270
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
4. Dose-effect relationships in neuroendocrine tumour liver metastases treated with [
Ramdhani K; Beijer-Verduin J; Ebbers SC; van Rooij R; Smits MLJ; Bruijnen RCG; de Jong HWAM; Lam MGEH; Braat AJAT
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2114-2123. PubMed ID: 38369678
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
Kim AY; Unger K; Wang H; Pishvaian MJ
BMC Cancer; 2016 Jul; 16():492. PubMed ID: 27430276
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis.
Friebe L; Freitag MT; Braun M; Nicolas G; Bauman A; Bushnell D; Christ E; Wild D
J Nucl Med; 2024 Feb; 65(2):228-235. PubMed ID: 38164592
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases.
Tsang ES; Loree JM; Davies JM; Gill S; Liu D; Ho S; Renouf DJ; Lim HJ; Kennecke HF
Can J Gastroenterol Hepatol; 2020; 2020():5104082. PubMed ID: 33299824
[TBL] [Abstract][Full Text] [Related]
8. The Landmark Series: Neuroendocrine Tumor Liver Metastases.
Gangi A; Howe JR
Ann Surg Oncol; 2020 Sep; 27(9):3270-3280. PubMed ID: 32632880
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Liver Transplantation after 90Y Radioembolization: Lessons from a Radiation Protection Incident.
Soret M; Maisonobe JA; Maksud P; Payen S; Allaire M; Savier E; Roux C; Lussey-Lepoutre C; Kas A
Health Phys; 2024 Mar; ():. PubMed ID: 38535982
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.
Braat MNGJA; Ebbers SC; Alsultan AA; Neek AO; Bruijnen RCG; Smits MLJ; de Bruijne J; Lam MGEH; Braat AJAT
Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132236
[TBL] [Abstract][Full Text] [Related]
11. Extrahepatic
Shea C; Lamberg H; Turk S; Sanogo M; Turgeon D; Nojkov B; Frey K; Raffel D
Nucl Med Mol Imaging; 2024 Apr; 58(2):86-91. PubMed ID: 38510819
[TBL] [Abstract][Full Text] [Related]
12. Erratum for: Expected and Unexpected Imaging Findings after
Spina JC; Hume I; Pelaez A; Peralta O; Quadrelli M; Garcia Monaco R
Radiographics; 2023 Dec; 43(12):e239013. PubMed ID: 38032819
[No Abstract] [Full Text] [Related]
13. Radioembolization Working in Synergy with Chemotherapy in NET, but can Dosimetry Bring us Even Further?
Smits M; Braat A
Cardiovasc Intervent Radiol; 2024 Apr; 47(4):529-530. PubMed ID: 38514503
[No Abstract] [Full Text] [Related]
14. Radioembolization with
Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
[TBL] [Abstract][Full Text] [Related]
16. Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.
Criss CR; Makary MS
Curr Oncol; 2024 Apr; 31(4):2076-2091. PubMed ID: 38668057
[TBL] [Abstract][Full Text] [Related]
17. Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors.
Hoogenkamp DS; de Wit-van der Veen LJ; Huizing DMV; Tesselaar MET; van Leeuwaarde RS; Stokkel MPM; Lam MGEH; Braat AJAT
Curr Oncol Rep; 2024 May; 26(5):551-561. PubMed ID: 38598035
[TBL] [Abstract][Full Text] [Related]
18. Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy.
Rabei R; Fidelman N
Curr Treat Options Oncol; 2023 Dec; 24(12):1994-2004. PubMed ID: 38100020
[TBL] [Abstract][Full Text] [Related]
19. A Clinical Guide to Peptide Receptor Radionuclide Therapy with
Becx MN; Minczeles NS; Brabander T; de Herder WW; Nonnekens J; Hofland J
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497273
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
